The global point of care diagnostics market valued at US$ 14.26 billion in 2023, is forecasted to grow at a robust CAGR of ...

The global lateral flow assay (LFA) market, valued at USD 4.3 billion in 2023, is projected to grow steadily at a CAGR of 4.7 ...

The outlook and technical action suggest Abbott Laboratories (NYSE: ABT) will lead healthcare names like Johnson & Johnson ...

Abbott Laboratories (NYSE: NYSE:ABT) has demonstrated resilience and growth potential in the healthcare sector, maintaining a strong financial profile despite facing various challenges. According to ...

Abbott said under Operation Lone Star, state law enforcement has apprehended more than half a million undocumented immigrants, stopped more than 140,000 attempted "illegal entries," arrested over ...

Abbott Laboratories (ABT) reports robust sales growth and improved margins, setting the stage for continued success in 2025 ...

The FDA granted marketing clearances for infectious disease tests, updates to a digital pathology system, and immunoassays for chronic diseases.

Abbott reported $9.34 billion in diagnostics revenues in 2024, down 7 percent on a reported basis from $9.99 billion in 2023 and down 4 percent on an organic basis. Excluding COVID-19 testing-related ...

Abbott Laboratories (NYSE:ABT) reported fourth-quarter sales of $10.97 billion, up 7.2% year over year, missing the consensus ...

For the full calendar of 2024, Abbott recorded sales of $41.95 billion, following the launches last year of a new heart valve ...

Abbott’s device business has been a bright spot as litigation over its baby formula products and declining demand for its ...

Welcome to Abbott's fourth quarter 2024 earnings conference call. [Operator instructions] This call is being recorded by ...